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Abstract  
Background: Limited treatments with distinct mechanism of action are available for patients with 
platinum-refractory advanced or metastatic urothelial carcinoma. We assessed efficacy and safety of 
treatment with docetaxel plus ramucirumab, a human IgG1 VEGFR-2 antagonist, or placebo in this 
patient population.  
 
Methods: In this randomised, double-blind, phase 3 trial, patients with advanced or metastatic urothelial 
carcinoma who progressed during or after platinum-based chemotherapy were enroled. Prior treatment 
with one immune checkpoint inhibitor was permitted. Patients were randomised (1:1) to receive 
docetaxel 75 mg/m2 with ramucirumab 10 mg/kg or placebo on day 1 of repeating 21-day cycles until 
disease progression or other discontinuation criteria were met. The primary endpoint was investigator-
assessed progression-free survival. This study is registered with ClinicalTrials.gov, number 
NCT02426125. 
 
Findings: Between July 2015 and April 2017, a total of 530 patients from 124 sites in 23 countries 
were randomised to receive ramucirumab plus docetaxel (n=263) or placebo plus docetaxel (n=267). 
Progression-free survival was significantly prolonged in patients treated with ramucirumab plus 
docetaxel versus placebo plus docetaxel (median, 4·07 vs 2·76 months; HR, 0·757; 95% CI, 0·607-
0·943; P=0·0118). A blinded central analysis demonstrated consistent progression-free survival 
results (HR, 0·672; 95% CI, 0·536-0·842; P=0·0005). Objective response rate was 24·5% (95% CI, 
18·8-30·3) in the ramucirumab arm and 14·0% (95% CI, 9·4-18·6) in the placebo arm. Grade ≥3 
adverse events were reported at a similar frequency in both arms (60 vs 62%) with no unexpected 
toxicities. 
 
Interpretation: Ramucirumab plus docetaxel is the first regimen in a phase 3 study to show superior 
progression-free survival over chemotherapy in patients with platinum-refractory advanced urothelial 
carcinoma.  
 
Funding: Eli Lilly and Company 
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Introduction 
Platinum-based combination chemotherapy is standard frontline treatment for patients with advanced 
or metastatic urothelial carcinoma (UC) with a median overall survival (OS) of 11–15 months, 
depending on the type of platinum chemotherapy that can be administered and baseline clinical 
prognostic factors.1-4 Despite an objective response rate (ORR) of 40–70%, the duration of response 
is limited and most patients become refractory. Prognosis in refractory patients remains poor, with a 
median OS with single-agent cytotoxic therapy of approximately 7 months.5 
 
Immune checkpoint inhibitors targeting the programmed death 1 (PD-1) and its ligand (PD-L1) have 
shown clinical activity in patients with platinum-refractory UC. Accelerated or full approval has been 
granted in the United States to five agents of this class based on an ORR of 15-21%.6-10 However, 
many patients treated with immune checkpoint inhibitors have progressive disease as best response, 
highlighting other targets and treatments are needed.6-11  
 
Vascular endothelial growth factor receptors (VEGFR) 1 and 2 and their ligands are important 
mediators of tumour angiogenesis and contribute to the pathogenesis and progression of UC.11-19 
Ramucirumab is an immunoglobulin G1 monoclonal antibody that binds to the extracellular domain of 
VEGFR-2, competing with VEGF-A, -C, and -D.20 In a randomised phase 2 study in patients with 
platinum-refractory advanced or metastatic UC, ramucirumab plus docetaxel significantly improved 
median progression-free survival (PFS) over docetaxel (5·4 vs 2·8 months; hazard ratio [HR], 0·389; 
95% confidence interval [CI], 0·235-0·643; P =0·0002).13 To confirm these results, we conducted a 
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Methods 
Study design and participants 
We did this double-blind, multicentre randomized, phase 3 study at 124 investigative sites in 23 
countries (listed in the appendix). The full inclusion and exclusion criteria are provided in the appendix. 
Briefly, patients aged 18 years or older were eligible for enrolment if they had histologically or 
cytologically-confirmed carcinoma of pure or predominant transitional-cell histology; locally advanced 
or unresectable or metastatic disease extent; primary tumour originating from the bladder, urethra, 
ureter, or renal pelvis; and progression ≤14 months after platinum-containing chemotherapy (2 
additional months were allowed for screening and patient identification over the standard 12 months21). 
Prior treatment with one immune checkpoint inhibitor was permitted for patients who relapsed ≤24 
months from the end of a platinum-containing regimen, allowing an additional 10 months for patients 
who received both platinum and immune checkpoint inhibitors. Eastern Cooperative Oncology Group 
(ECOG) performance status of 0 or 1 was required. Key exclusion criteria included more than one prior 
systemic chemotherapy in the relapsed or metastatic setting (prior systemic therapy in the perioperative 
setting was not considered a prior line); prior systemic taxane; untreated brain metastases; 
haemoglobin <9 g/dL; and an arterial or venous thromboembolic event ≤ 6 months prior to 
randomisation.  
 
The trial was conducted in compliance with the Declaration of Helsinki, the International Conference on 
Harmonisation Guidelines for Good Clinical Practice, and applicable local regulations. The protocol was 
approved by the ethics committees of all participating centres, and all patients provided written informed 
consent before study entry. An independent data monitoring committee assessed unblinded safety data 
throughout the study.  
 
Randomisation and masking 
Patients were randomly assigned by a computer-generated random sequence using an interactive 
Web response system. Randomisation was stratified by geographic region (North America, East Asia, 
Europe/rest of the world); ECOG performance status at baseline (0 or 1); and visceral metastasis (yes 
or no), where visceral metastases involve the liver, lung, and/or bone. Patients, study staff, and the 
sponsor were masked to treatment assignment.  
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Procedures 
Patients were randomized to receive intravenous (IV) docetaxel 75 mg/m2 (60 mg/m2 in Korea, 
Taiwan and Japan) plus IV ramucirumab 10 mg/kg or placebo 10 mg/kg volume equivalent, on day 1 
of a 21-day cycle. Treatments were continued until disease progression or unacceptable toxicity.  
Docetaxel was limited to 6 cycles; up to 4 additional cycles could be given after sponsor approval. 
There was no planned crossover on disease progression. Dose modifications of any administered 
study drug were allowed according to protocol-defined criteria. The use of granulocyte-colony 
stimulating factors was permitted based on the American Society of Clinical Oncology guidelines.22 
 
We assessed tumour response radiographically according to RECIST version 1·1 at baseline, every 6 
weeks after randomisation for the first year, and then every 12 weeks thereafter. Following 
discontinuation, patients were followed for survival every 3 months. The appendix provides details of 
the timing of other assessments. Adverse events (AEs) were graded using the National Cancer 
Institute Common Terminology Criteria for AEs, version 4·0. Patient-reported outcomes (PROs) were 
assessed using the European Organisation for Research and Treatment of Cancer (EORTC) Quality 
of life Questionnaire-Core 30 (QLQ-C30, version 3·0) and the EQ-5D-5L questionnaire, which 
measure quality of life and health status, respectively. The QLQ-C30 was scored on a scale of 0 to 
100, according to the EORTC scoring manual, and the EQ-5D-5L index was calculated using the 
English value set.23 For the QLQ-C30, time to sustained deterioration was defined as time from 
randomisation to first ≥10-point worsening with no subsequent on-therapy assessment that returned 
to or improved from baseline score. 
 
Outcomes 
Primary endpoint was investigator-assessed PFS, defined as the time from randomisation until the 
first radiographic documentation of objective progression, or as death due to any cause. Secondary 
endpoints included OS, defined as the time from randomisation to death from any cause; ORR, 
defined as the proportion of patients with a best overall response of complete or partial response; 
disease control rate, defined as the proportion of patients with a best overall response of complete 
response, partial response or stable disease; duration of response, defined as the first date of 
complete or partial response until the first date of objective progression, or death; safety; PROs; 
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pharmacokinetics of ramucirumab; and immunogenicity of ramucirumab. The protocol provides the full 
assessment schedule.  
 
Statistical analysis 
We planned to enrol 524 patients in a 1:1 randomisation with the primary analysis to be conducted 
when at least 331 PFS events were observed from the first 437 randomised patients. The number of 
events provided 90% power to detect PFS superiority of ramucirumab plus docetaxel versus placebo 
plus docetaxel, assuming a HR of 0·70 with a 2-sided alpha of 0·05. The sample size was also 
adequately powered to show an OS superiority between the 2 arms, with an assumed HR of 0·75 
for ramucirumab plus docetaxel versus placebo plus docetaxel with at least 382 events, power 80%, 
and 2-sided type I error of 0·05.  
 
PFS and response were assessed in the first 437 patients of the intention-to-treat (ITT) population 
that included all randomised patients. PROs used the full ITT population. PFS was estimated using 
the Kaplan-Meier method, and outcomes were compared between arms using a stratified log-rank 
test. HRs and associated 95% CIs were estimated using a stratified Cox proportional hazard model. 
The PRO data were summarised descriptively. Time to sustained deterioration was compared using 
an unstratified log-rank test. Safety was assessed in all patients who received at least one dose of 
study medication. A gatekeeping design was implemented to assess PFS, OS, and ORR in a fixed 
sequential manner.  
 
Role of the Funder 
The trial was designed by the funder (Eli Lilly and Company), in collaboration with the scientific 
council (including authors: DPP, RdW, KNC, CNS, HN, and TP), and was responsible for data 
management, and statistical analysis. The funder interpreted data in collaboration with all authors and 
supported development of the report by providing medical writing and editorial assistance. All authors 
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Results 
Patients and Treatment 
Between July 2015 and April 2017, a total of 727 patients at 124 sites were screened, and 530 eligible 
patients were randomly assigned to receive ramucirumab plus docetaxel (n=263) or placebo plus 
docetaxel (n=267). Five patients in the ramucirumab arm and two in the placebo arm did not receive 
study treatment; therefore, the safety population comprised 523 patients (Figure 1). Baseline 
characteristics of the treatment arms were well balanced (Tables 1, S1, S2). Most patients (61%) had 
two or more adverse prognostic risk factors,24,25 including visceral metastases (70%), haemoglobin 
<10 g/dL (14%), ECOG performance status score >0 (53%), and time since completion or 
discontinuation of previous therapy of <3 months (45%) (Table 1).  
Data cutoff for the current analysis was April 21, 2017, at which time 341 of the first 437 randomised 
patients had disease progression or died. At data cutoff, 49 (19%) of 263 patients in the ramucirumab 
arm and 36 (13%) of 267 patients in the placebo arm continued to receive study treatment. Median 
follow-up duration in the full ITT population was 5·0 months (interquartile range [IQR], 2·3–8·9). 
Median therapy duration was 12·2 weeks (IQR, 6·0–21·0) with ramucirumab and 9·9 weeks (IQR, 6·0–
20·9) with placebo. The median number of cycles of docetaxel was four (IQR, 2–6) in the 
ramucirumab arm and three (IQR, 2–6) in the placebo arm (Table S3). Ninety-three (36%) of 258 
patients in the ramucirumab arm and 84 (32%) of 265 patients in the placebo arm completed at least 
six cycles of docetaxel therapy; median relative dose intensities were 98·3% (IQR, 90·9–100·1) and 
98·8% (IQR, 92·9–100·1), respectively. Patients who continued with ramucirumab or placebo 
monotherapy after the end of docetaxel (n=64 versus n=60) received a median of three (IQR, 2–7) 
additional cycles of treatment in the ramucirumab arm and two (IQR, 1–5) in the placebo arm.  
 
Outcomes 
Table S4 summarises the efficacy results. In the 437 ITT population, 341 PFS events occurred 
(ramucirumab arm: n=158 [73%]; placebo arm: n=183 [83%]). Median PFS was 4·07 months in the 
ramucirumab arm and 2·76 months in the placebo arm (stratified HR, 0·757; 95% CI, 0·607–0·943; 
P=0·0118; Figure 2A). The estimated PFS rate at 12 months was 11·9% (95% CI, 7·1–18·0) in the 
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ramucirumab arm and 4·5% (95% CI, 1·5–10·1) in the placebo arm. A blinded independent central 
analysis demonstrated consistent PFS results (stratified HR, 0·672; 95% CI, 0·536–0·842; P=0·0005; 
Figure 2B). In prespecified subgroup analyses for PFS, the addition of ramucirumab to docetaxel 
improved PFS across most patient subgroups (Figure 3). 
Investigator-assessed ORR in the 437 ITT population was 24·5% (95% CI, 18·8–30·3) in the 
ramucirumab arm and 14·0% (95% CI, 9·4–18·6) in the placebo arm, with non-overlapping confidence 
intervals (Table S4). This included nine (4·2%) complete responses in the ramucirumab arm and three 
(1·4%) complete responses in the placebo arm. ORR by blinded independent central analysis was 
22·2% (95% CI, 16·7–27·8) in the ramucirumab arm and 12·7% (95% CI, 8·3–17·1) in the placebo arm. 
Due to gatekeeping trial design, ORR superiority will be formally tested if the OS superiority test is 
positive. Median duration of response was 5·65 months (95% CI, 3·9–7·1) for the ramucirumab arm and 
4·17 months (95% CI, 2·9–5·5) for the placebo arm. Of the patients who received a prior immune 
checkpoint inhibitor, 5 (35·7%) of 14 patients in the ramucirumab arm and 2 (10·5%) of 19 in the placebo 
arm had an objective response to treatment. Disease control occurred in 63·4% (95% CI, 57·0–69·8) of 
patients in the ramucirumab arm and 56·1% (95% CI, 49·6–62·7) in the placebo arm. Most patients 
experienced a reduction in tumour burden, with an observed increase in PFS, in the ramucirumab arm 
(64%) (Figure 4). Reductions in tumour burden occurred less frequently in the placebo arm (47%). As 
of the data cutoff, OS results were not mature, with 219 events. 
Compliance for completion of the PRO questionnaires in the 530 ITT population was 97% in both 
treatment arms at baseline and was ≥85% at all on-therapy post-baseline visits. Baseline scores were 
similar between treatment arms. Mean scores for global quality of life and the EQ-5D-5L index were 
relatively unchanged over time, with no differences between treatment arms (Figure 5).  There was no 
difference in time to sustained deterioration in global quality of life (unstratified HR, 0·931; 95% CI, 
0·701–1·235; P=0·610).  
Following administration of ramucirumab 10 mg/kg every 3 weeks in combination with docetaxel to 
patients with urothelial carcinoma, the geometric mean trough concentrations prior to doses 2, 3 and 5 
were 15, 23, and 34 µg/mL, respectively. These data are consistent with previous studies where 
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ramucirumab was administered to patients with various types of cancer using this regimen. Of the 258 
treated patients in the ramucirumab arm, there were 185 whose serum was analysed for the presence 
of anti-ramucirumab antibodies; 19 (10%) had positive samples at baseline and 3 (2%) had treatment-
emergent anti-ramucirumab antibodies. 
Safety 
The most frequently reported treatment-emergent AEs in either treatment arm (any grade) were 
fatigue, alopecia, diarrhoea, decreased appetite, and nausea (Table 2). These occurred 
predominantly at grade 1–2 severity. Grade ≥3 AEs were reported at a similar frequency in both 
treatment arms; 60% of patients in the ramucirumab arm and 62% in the placebo arm. No grade ≥ 3 
AE was observed that showed a difference in incidence of 5% or more in the ramucirumab arm 
compared to placebo. Grade ≥3 anaemia was less common in the ramucirumab arm (3 vs 11%). The 
incidence of grade ≥3 neutropenia (15 vs 14%) was similar in both treatment groups. Granulocyte 
colony-stimulating factor use was similar in both treatment groups: 41% in the ramucirumab arm and 
42% in the placebo arm.  
 
AEs of interest, based on the known safety profile of other antiangiogenic therapies and prior clinical 
experience with ramucirumab, are shown in Table 2. Grade 1-2 events of epistaxis (14 vs 5%), 
hypertension (11 vs 5%), haematuria (10 vs 6%), and proteinuria (9 vs 3%) were each reported more 
frequently in the ramucirumab arm. The incidence of venous (2 vs 5%) and arterial (3 vs <1%) 
thromboembolic events were low and reported at similar frequency in both treatment groups.  
 
AEs leading to at least one dose adjustment (reduction, delay or omission of any study drug) were 
reported in 88 (34%) patients in the ramucirumab arm and 82 (31%) in the placebo arm. The most 
common AE leading to dose adjustments for ramucirumab compared with placebo was febrile 
neutropenia (4 vs 4%). AEs leading to discontinuation of any study treatment occurred in 39 (15%) 
patients in the ramucirumab arm and 19 (7%) in the placebo arm. Sepsis was the most common AE 
leading to treatment discontinuation of any therapy; this occurred in five (2%) patients in ramucirumab 
arm and no patients in the placebo arm.  
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Serious AEs were reported for 100 (39%) patients in the ramucirumab arm and 104 (39%) in the placebo 
arm; these were deemed to be related by the investigator to study treatment in 63 (24%) and 54 (20%), 
respectively. Including events related by the investigator to disease progression, AEs with an outcome 
of death on treatment or within 30 days of discontinuation were reported for 38 (15%) patients in the 
ramucirumab arm and 43 (16%) in the placebo arm; these were deemed to be related by the investigator 
to study treatment in 8 (3%) and 5 (2%) patients, respectively. Sepsis was the most common AE leading 
to death on therapy (Table S5), occurring in 4 (2%) patients in ramucirumab arm and no patients in the 
placebo arm. One fatal event of neutropenic sepsis was reported in the ramucirumab arm.  
 
Discussion 
The RANGE study demonstrated the addition of ramucirumab to docetaxel was associated with a 
statistically significant improvement in PFS in patients with platinum-refractory advanced UC. In this 
advanced patient population, PFS outcomes were consistent across almost all major subgroups 
examined and confirmed by blinded central review. The majority of patients in this trial had two or 
more adverse prognostic risk factors at baseline, including the presence of visceral metastases. A 
consistent PFS benefit was observed for patients treated with ramucirumab plus docetaxel, 
irrespective of these risk factors, demonstrating broad applicability of this regimen. The median PFS 
of 2·76 months that was observed in the placebo arm is consistent with historical data in the second-
line setting, such that the observed improvement in the ramucirumab arm was not attributable to 
underperformance of the control arm.5,13 
 
OS data are immature at this time precluding formal statistical analysis for ORR in accordance with 
the order of analyses specified in the statistical analysis plan. However, a higher proportion of patients 
achieved an objective response in the ramucirumab arm (24·5%), including nine complete responses, 
than in the placebo arm (14·0%) with non-overlapping 95% CIs. The ORR was consistent with that of 
the phase 2 study of this treatment regimen and higher when indirectly compared with historical 
chemotherapy studies.5,13,26 The ORR observed in the ramucirumab arm in our study is also in line 
with those seen with immune checkpoint inhibitors in other studies, although duration of response 
appears longer with immune checkpoint inhibitors.6 The disease control rate of 63.4% in our study 
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compares favourably to single-agent chemotherapy or immune checkpoint inhibitors in other studies, 
underlining the active nature of this regimen in biomarker-unselected patients. 
 
The combination of ramucirumab and docetaxel revealed no unexpected safety findings. Most 
toxicities were of grade 1–2 severity and manageable with supportive care alone or with dose 
reductions, as evident by the high median relative dose-intensity for all study drugs. Overall, the 
addition of ramucirumab to docetaxel was not associated with an increase in occurrence of grade ≥3 
toxicities typically associated with docetaxel in this patient population. Consistent with Phase 2 data,13 
the most common haematological toxicity in our study was neutropenia and was reported at a similar 
incidence in both treatment arms; anaemia was less common in the ramucirumab arm. The incidence 
of toxicities identified as potential class effects of antiangiogenic therapies, such as grade 1–2 
hypertension and bleeding, occurred at a higher frequency in the ramucirumab arm. In addition, the 
PRO analyses indicated that there was no negative impact on quality of life. This is particularly 
important for these patients, as most have a short life expectancy.  
 
Phase 2 and 3 studies have demonstrated that approximately 20% of patients with platinum-refractory 
UC demonstrate an objective response to immune checkpoint inhibition.6-8  Strategies to increase 
ORR include combinations of PD-1/PD-L1 inhibitors with other immune checkpoint inhibitors, 
chemotherapy, or antiangiogenic agents.5,27-30  Ramucirumab in combination with PD-1/PD-L1 
inhibitors has demonstrated promising clinical activity in multiple tumour types in the phase 1 setting, 
with no unexpected toxicities.28,30,31 Although the pool of patients in RANGE who had been treated 
with prior immune checkpoint inhibitors is limited, the reported outcome is similar to that observed in 
all patients. Based on the reported efficacy and tolerability, ramucirumab plus docetaxel is also an 
alternative treatment regimen in the post-immune checkpoint or immune checkpoint inhibitor ineligible 
setting.  
 
In conclusion, these findings are consistent with results from our previous phase 2 study in which 
ramucirumab combined with docetaxel improved PFS in patients with platinum-refractory advanced or 
metastatic UC. Ramucirumab is the only antiangiogenic agent with proven clinical activity in this patient 
population and, to our knowledge, RANGE represents the first phase 3 study to demonstrate a PFS 
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advantage over chemotherapy alone. No additive or unexpected toxicities were observed when 
ramucirumab was combined with docetaxel. Together, these studies suggest a favorable benefit-to-risk 
ratio for this combination treatment and may represent a new regimen for this patient population.  
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Research in context 
Evidence before this study 
In the development of the study design and protocol, we conducted a systematic review of the 
published scientific literature. We searched PubMed, with no time restrictions; abstracts of major 
oncology congresses; and clinical trial websites including ClinicalTrials.gov, for English-language 
preclinical reports and clinical trials assessing chemotherapy, antiangiogenic therapies, and a 
combination of these methods in urothelial carcinoma. The findings of this search included multiple 
single-agent cytotoxic therapies, such as docetaxel, all with modest activity in this patient population. 
Search results for clinical data in support of this trial included a randomised phase 2 study 
(NCT01282463) in patients with platinum-refractory advanced or metastatic UC, where ramucirumab 
plus docetaxel significantly improved median progression-free survival (PFS) over docetaxel. As the 
protocol was being developed, emerging evidence suggested immune checkpoint inhibitors targeting 
the programmed death 1 (PD-1) and its ligand (PD-L1) demonstrated clinical activity in a subset of 
patients with platinum-refractory UC. On the basis of this emerging evidence, we included patients 
who received one prior immune checkpoint inhibitor. Upon review of the scientific literature and 
discussions with clinicians, researchers, and regulatory agencies, we conducted this phase 3 study.  
Ramu-00084475 Draft for Lancet 26-July-2017 
 
Added value of this study 
Our findings show that in patients with platinum-refractory advanced or metastatic urothelial carcinoma, 
ramucirumab plus docetaxel can improve PFS and the objective response rate, without additive toxicity 
or compromising quality of life when compared to placebo plus docetaxel. The response rate observed 
in our trial is in line with those seen with immune checkpoint inhibitors in other studies. Taken together 
with results from our prior phase 2 study in a similar patient population, we provide significant data 
showing inhibition of VEGFR-2-mediated signaling yields meaningful clinical activity in patients with 
platinum-refractory advanced or metastatic urothelial carcinoma. Ramucirumab is the only 
antiangiogenic agent with meaningful clinical activity in this patient population and, to our knowledge, 
RANGE is the first phase 3 study to demonstrate a PFS advantage over chemotherapy alone in 
platinum-refractory advanced or metastatic urothelial carcinoma. 
 
Implications of all the available evidence 
The RANGE trial design was appropriate for the treatment of a patient population with platinum-
refractory advanced or metastatic urothelial carcinoma and can be generalized to clinical practice. The 
results confirm the benefit of the addition of an anti-VEGFR2 antibody to standard chemotherapy in this 
setting and represent clinically meaningful progress in the treatment of urothelial carcinoma.  
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Table 1. Baseline demographics and characteristics (ITT; n=530) 
  
Ramucirumab +  
docetaxel 
(n=263) 
Placebo +  
docetaxel 
(n=267) 
Median age, years (range) 65 (34-86) 66 (32-83) 
    ≥ 65 years 139 (53) 152 (57) 
Male sex 213 (81) 215 (81) 
Race   
White 204 (78) 204 (76) 
Asian 54 (21) 61 (23) 
ECOG performance status   
0 121 (46) 125 (47) 
1 138 (52) 142 (53) 
Geographical region   
    North America 24 (9) 24 (9) 
    Europe/Other 186 (71) 186 (70) 
    East Asia 53 (20) 57 (21) 
Histology   
    Pure transitional cell 201 (76) 209 (78) 
    Mixed histology 55 (21) 50 (19) 
    Missing  7 (3) 8 (3) 
Bladder as primary site of tumour 169 (64) 170 (64) 
Visceral disease 182 (69) 188 (70) 
    Lung metastases 99 (38) 121 (45) 
    Liver metastases 78 (30) 69 (26) 
    Bone metastases 56 (21) 53 (20) 
    Adrenal gland 16 (6) 12 (4) 
    Kidney 12 (5) 10 (4) 
    Spleen 4 (2) 5 (2) 
    Other 35 (13) 28 (10) 
Lymph node only metastases 52 (20) 45 (17) 
Creatinine clearance   
   <60 mL/min 106 (40) 118 (44) 
   ≥60 mL/min 151 (57) 146 (55) 
   Missing 6 (2) 3 (1) 
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Haemoglobin concentration <10 g/dL 37 (14) 36 (13) 
Completion or disc of most recent therapy < 3 months 115 (44) 122 (46) 
Number of Bellmunt risk factors†   
    0 3 (1) 0  
    1 102 (39) 101 (38) 
    2 88 (33) 113 (42) 
    3 69 (26) 45 (17) 
    4 1 (<1) 8 (3) 
Prior adjuvant therapy   
    Adjuvant 38 (14) 61 (23) 
    Neo-adjuvant 40 (15) 37 (14) 
    No prior adjuvant 168 (64) 155 (58) 
    Missing  17 (6) 14 (5) 
Prior therapies‡   
   Cisplatin-based 159 (60) 182 (68) 
   Carboplatin-based 95 (36) 78 (29) 
   Immune checkpoint inhibitor 18 (7) 26 (10) 
Abbreviation: disc = discontinuation; ECOG = Eastern Cooperative Oncology Group; ITT = intent-to-
treat. 
Data are n (%) unless otherwise indicated. 
†Bellmunt risk factors24,25 included visceral metastases, hemoglobin <10 g/dL, ECOG performance 
status score >0, and time since completion or discontinuation of previous therapy of <3 months.  
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Table 2: Treatment-emergent adverse events (safety population, n=523) 
 Ramucirumab + docetaxel 
(n=258) 
Placebo + docetaxel 
(n=265) 
 Any Grade Grade ≥3 Any Grade Grade ≥3 
Any 244 (95) 156 (60) 251 (95) 163 (62) 
   Fatigue† 110 (43) 20 (8) 121  (46) 25 (9) 
   Alopecia 63 (24) 0 92 (35) 1 (<1) 
   Diarrhoea 75 (29) 7 (3) 56 (21) 7 (3) 
   Decrease appetite 73 (28) 8 (3) 61 (23) 5 (2) 
   Nausea 63 (24) 1 (<1) 52 (20) 3 (1) 
   Stomatitis 61 (24) 8 (3) 29 (11) 0 
   Pyrexia 42 (16) 1 (<1) 41 (15) 1 (<1) 
   Vomiting 38 (15) 3 (1) 37 (14) 2 (<1) 
   Neuropathy† 31 (12) 0 43 (16) 2 (<1) 
   Constipation 29 (11) 1 (<1) 43 (16) 1 (<1) 
   Urinary tract infection 32 (12) 10 (4) 38 (14) 11 (4) 
   Peripheral oedema 36 (14) 0 30 (11) 1 (<1) 
   Dyspnoea 30 (12) 5 (2) 30 (11) 5 (2) 
   Asthenia 26 (10) 3 (1) 22 (8) 4 (2) 
   Dysgeusia 30 (12) 0 17 (6) 0 
Haematological     
   Neutropenia† 51 (20) 39 (15) 44 (17) 36 (14) 
   Febrile neutropenia 25 (10) 25 (10) 17 (6) 17 (6) 
   Anaemia 40 (16) 7 (3) 64 (24) 28 (11) 
   Leukopenia† 26 (10) 17 (7) 24 (9) 21 (8) 
AEs of special interest     
   Bleeding or haemorrhage† 67 (26) 8 (3) 46 (17) 12 (5) 
      Epistaxis 36 (14) 0 13 (5) 0  
      Haematuria 27 (10) 5 (2) 17 (6) 5 (2) 
      GI haemorrhage 10 (4) 2 (<1) 10 (4) 3 (1) 
      Pulmonary haemorrhage 1 (<1) 0 0 0 
   Hypertension† 29 (11) 15 (6) 12 (5) 5 (2) 
   Renal failure† 15 (6) 8 (3) 19 (7) 2 (<1) 
   Proteinuria 23 (9) 2 (<1) 8 (3) 1 (<1) 
   Venous thromboembolic† 6 (2) 1 (<1) 13 (5) 5 (2) 
   Arterial thromboembolic† 8 (3) 6 (2) 2 (<1) 0 
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   Fistula† 5 (2) 3 (1) 2 (<1) 2 (<1) 
   Congestive heart failure† 3 (1) 2 (<1) 1 (<1) 1 (<1) 
   GI perforation† 3 (1) 2 (<1) 1 (<1) 1 (<1) 
Abbreviation: AE = adverse event; GI = gastrointestinal.  
Data are number (%). The table shows treatment-emergent adverse events occurring in at least 10% 
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Figure 1: Trial Profile 
 
 
Figure 2: Kaplan-Meier plots for progression-free survival (n=437). (A) investigator-assessed 
(B) independent central review. Abbreviations: CI = confidence interval; HR = hazard 
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Figure 3: Progression-free survival subgroup analyses, first 437 randomised patients 
Abbreviations: CI = confidence interval; ECOG PS = Eastern Cooperative Oncology Group 
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Figure 4: Best percent change from baseline in tumour size vs progression-free survival (PFS), 
first 437 randomised patients 
 
Best percentage change of targeted lesions from baseline versus PFS. Patients (x-axis) were ordered 
by best percentage change of targeted lesions from baseline (y-axis) and color coded for best 
response according to RECIST version 1·1. PFS time (z-axis) is shown as observed or censored at 
time of data cutoff. Abbreviations: CR = complete response; NE = not evaluable; PD = progressive 
disease; PR = partial response; SD = stable disease; ORR = objective response rate. ORR was 
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Figure 5: Patient-reported Outcome Scores by Visit: (A) EORTC QLQ-C30 Global Quality of Life 
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Circles represent means scores and bars represent standard deviation. (A) Scores range from 0 to 
100, with higher scores representing better quality of life. (B) Scores range from -0·281 to 1 (displayed 
as 0-1), with higher scores representing better health status.These figures offset data from the 
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APPENDIX 
Study Protocol (attached separately) 
List of Principal Investigators 
Investigator Name Site Address 
Australia 






Thean Hsiang Tan, MD  
 
Royal Adelaide Hospital 
North Terrace, 
Adelaide, SA, 5000 
Australia 
Elizabeth Jane Hovey, MD Prince Of Wales Hospital 
Barker Street, 
Randwick, NSW, 2031 
Australia 
Timothy Dudley Clay, MD 
 
Siobhan Su Wan Ng 
 
St John of God Hospital –Subiaco 
12 Salvado Road, 
Subiaco, WA, 6008 
Australia 
Belgium 




Jean-Pascal Machiels, MD Cliniques Universitaires Saint-Luc 
Avenue Hippocrate, 10 
Uro-oncologie (étage -1 Route 389) 
Brussels,1200 
Belgium 





Susanna Yee-Shan Cheng, MD  
 
Centre- Odette Cancer Ctr. T2-034 
2075 Bayview Avenue 
Toronto, Ontario, M4N 3M5 
Canada 
Kim Nguyen Chi, MD British Columbia Cancer Agency 
600 West 10th Avenue 
Vancouver, British Columbia, V5Z 4E6 Canada 
Cristiano Ferrario, MD 
 
Jewish General Hospital 
3755 Chemin Cote Ste-catherine 
Pavilion E 
Montreal, Quebec, H3T 1E2 
Canada 
Denmark 
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Investigator Name Site Address 
Lisa Sengeloev, MD Herlev Hospital  
Herlevringvej 75 
Onkologisk Afdeling  54 B1 
Herlev, 2730 
Denmark 
Niels Viggo Jensen, MD 
 
Odense Universitetshospital 
Sdr. Boulevard 29 
Odense C, SYD, 5000 
Denmark 
France 
Constance Thibault, MD Hopital Europeen Georges Pompidou 
20-40 Rue Leblanc 
75015 Paris 
France 
Brigitte Laguerre, MD 
 
Centre Eugene Marquis 
Avenue Bataille Flandres-Dunkerque  
Bp 
35062 Rennes Cedex 
France 
Fredrik Laestadius, MD 
 
Centre Oscar Lambret 
3 Rue Frederic Combemale 
Bp 307 
59020 Lille Cedex 
France 
Florence Joly, MD 
 
Centre Francois Baclesse 
3 Avenue General Harris, Bp 5026  
14076 Caen Cedex 5 
France 
Aude Flechon, MD 
 
Centre Leon Berard 
28, Rue Laennec  
69373 Lyon Cedex 08 
France 
Stéphane Culine, MD 
 
Hopital Saint-Louis 
1, Avenue Claude Vellefaux  
75475 Paris Cedex 10 
France 
Catherine Becht, MD 
 
Centre de cancérologie du Grand Montpellier 




Günter Niegisch, MD Universitätsklinikum Düsseldorf 
Moorenstraße 5 
Düsseldorf, NORDRHEIN-WESTFALEN, 40225  
Germany 
Michael Stöckle, MD 
 
Universitätsklinikum Des Saarlandes 
Kirrberger Straße 1 
Urologische Klinik, Gebäude 6 
Homburg,SAARLAND, 66421 
Germany 
Marc-Oliver Grimm, MD 
 




Georgios Gakis, MD Klinikum Der Eberhard-Karls-Universität Tübingen 
Hoppe-Seyler-Straße 3 
Tübingen,BADEN-WÜRTTEMBERG, 72076  
Germany 
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Wolfgang Schultze-Seemann, MD 
 
Universitätsklinikum Freiburg 
Hugstetter Straße 55 
Klinik Für Urologie 
Freiburg Im Breisgau, BADEN-WÜRTTEMBERG, 79106  
Germany 
Greece 
Haralambos Kalofonos, MD 
 
University General Hospital Of Patras 
Rio 
Patras, ACHAIA, 26504 
Greece 
Dimitrios Mavroudis, MD 
 
University General Hospital Of Heraklion 
Stavrakia And Voutes 
Heraklion, CRETE, 71110 
Greece 
Christos Papandreou, MD 
 
Vasilis Karavasilis, MD  
 
General Hospital Of Thessaloniki Papageorgiou 
Ring Road 
N. Efkarpia, THESSALONIKI, 56403 
Greece 
Aristotelis Bamias, MD 
 
General Hospital Of Athens 'Alexandra' 
80 Vasilissis Sofias Ave 
Athens, ATTICA, 115 28 
Greece 
Hungary 
Janos Révész, MD 
 
Borsod-abauj-Zemplen Megyei Korhaz Es Egyetemi Oktato 
Korhaz 
Szentpeteri Kapu 72-76 
Miskolc,BAZ MEGYE, 3526 
Hungary 
Lajos Geczi, MD 
 
Orszagos Onkologiai Intezet 




Eli Rosenbaum, MD 
 
Rabin Medical Center 
39 Jabotinski St. 
Petach Tikva, 4941492 
Israel 
Raya Leibowitz-Amit, MD 
 
Chaim Sheba Medical Center 
Tel Hashomer  
Tel Hashomer, RAMAT GAN, 5265601  
Israel 
Daniel Kejzman, MD 
 
Meir Medical Center 
59 Tchernichovski St., 
Kfar Saba, 4428164 
Israel 
Avivit Peer, MD 
 
Rambam Medical Center 
8 Haaliya Hashniya St. Pob 9602  
Haifa, 3525408 
Israel 
David Sarid, MD 
 
Tel Aviv Sourasky Medical Center 
6 Weizman St.,  
Tel-Aviv Jaffa, 6423906  
Israel 
Italy 
Giorgio Vittorio Scagliotti, MD 
 
 
Azienda Ospedaliero - Universitaria S. Luigi Gonzaga 
Regione Gonzole, 10  
10043  Orbassano, TORINO 
Italy 
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Cora N. Sternberg, MD 
 
Azienda Ospedaliera  S. Camillo Forlanini 
Circonvallazione Gianicolense, 87 00152 Roma 
Italy 
Giampaolo Tortora, MD 
 
Ospedale Borgo Roma 
Piazzale Ludovico Antonio Scuro, 10 37134 Verona 
Italy 
Sergio Bracarda, MD 
 
Ospedale San Donato 
Via Pietro Nenni, 20  
52100 Arezzo 
Italy 
Andrea Necchi, MD 
 
Istituto Nazionale Dei Tumori 
Via Giacomo Venezian, 1  
20133 Milano 
Italy 
Francesco Massari, MD 
 
Ospedale Malpighi-Policlinico di S Orsola 




Takahiro Osawa MD  
 
Naoto Miyajima MD  
 
Nobuo Shinohara MD  
 
Hokkaido University Hospital 
Kita 14, Nishi 5, Kita-Ku 
Sapporo, HOKKAIDO, 060-8648 
Japan 
Fumimasa Fukuta, MD 
 
Sapporo Medical University Hospital 
16-291  Minami-1jyo-nishi Chuo-ku 
Sapporo, HOKKAIDO, 060-8543 
Japan 
Chikara Ohyama, MD 
 
 
Hirosaki University Hospital 
53 Hon-cho 
Hirosaki, AOMORI, 036-8563 
Japan 
Wataru Obara, MD 
 
Iwate Medical University Hospital 
19-1, Uchimaru 
Morioka, IWATE, 020-8505 
Japan 
Shinichi Yamashita, MD 
 
Tohoku University Hospital 
1-1, Seiryo-cho Aoba-Ku 
Sendai, MIYAGI, 980-8574 
Japan 
Yoshihiko Tomita, MD 
 
Niigata University Medical & Dental Hospital 
1-754,Asahimachidori,Chuo-ku 
Niigata, NIIGATA, 951-8520 
Japan 
Koji Kawai, MD 
 
Tsukuba University Hospital 
2-1-1 Amakubo 
Tsukuba, IBARAKI, 305-8576 
Japan 
Satoshi Fukasawa, MD 
 
Chiba Cancer Center 
666-2 Nitona-cho Chuo-Ku 
Chiba, CHIBA, 260-8717 
Japan 
Nobuaki Matsubara, MD 
 
National Cancer Center Hospital East 
6-5-1 Kashiwanoha 
Kashiwa, CHIBA, 277 8577 
Japan 
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Masafumi Oyama, MD 
 
Saitama Medical University International Medical Center 
1397-1 Yamane 
Hidaka, SAITAMA, 350-1298 
Japan 
Junji Yonese, MD 
 
The Cancer Institute Hospital Of JFCR 
3-8-31 Ariake 
Koto-Ku, TOKYO, 135-8550 
Japan 
Masayoshi Nagata, MD 
 
Juntendo University Hospital 
3-1-3 Hongo 
Bunkyo-Ku, TOKYO, 113-8431 
Japan 
Motohide Uemura, MD 
 
Osaka University Hospital 
2-15 Yamadaoka 
Suita-Shi, OSAKA, 565-0871 
Japan 
Kazuo Nishimura, MD 
 
Osaka International Cancer Institute 
3-1-69 Otemae Chuou-Ku 
Osaka, OSAKA, 541-8567 
Japan 
Mutsushi Kawakita, MD 
 
Kobe City Medical Center General Hospital 
2-1-1, Minami-Machi, Minatojima, Chuo-Ku 
Kobe, HYOGO, 650-0047 
Japan 
Hiroyuki Tsunemori, MD 
 
Kagawa University Hospital 
1750-1 Ikenobe, Miki-cho 
Kita-gun, Kagawa, 761-0793 
Japan 
Katsuyoshi Hashine, MD 
 
National Hospital Organization Shikoku Cancer Center 
160 Kou Minamiumemoto-Machi 
Matsuyama, EHIME, 791-0280 
Japan 
Junichi Inokuchi, MD  
 
Akira Yokomizo, MD 
 
Kyushu University Hospital 
3-1-1 Maidashi Higashi-Ku 
Fukuoka, FUKUOKA, 812-8582 
Japan 
Satoshi Nagamori, MD 
 
National Hospital Organization Hokkaido Cancer Center 
2-3-54 Kikusui-4jyo Shiroishi-Ku 
Sapporo, HOKKAIDO, 003-0804 
Japan 
Korea 
Jae-Lyun Lee, MD 
 
Asan Medical Center 
88, Olympic-Ro, 43-Gil, Songpa-Gu 
Seoul, 05505 
Korea, South 
Hyo Jin Lee, MD 
 
Chungnam National University Hospital 
282 Munhwa-ro, Jung-gu 
Daejeon, 35015 
Korea, South 
Se Hoon Park, MD 
 
Samsung Medical Center 
81 Irwon-ro, Gangnam-gu 
Seoul, 06351,  
Korea, South 
Sun Young Rha, MD 
 
Severance Hospital 
50-1 Yonsei-ro, Seodaemun-gu 
Seoul, 03722 
Korea, South 
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Yu Jung Kim, MD 
 
Seoul National University Bundang Hospital 
300 Gumi-dong, Bundang-gu 
Seongnam-si, Gyeongg1-do, 13620 
Korea, South 
Yun-Gyoo Lee, MD 
 
Kangbuk Samsung Hosp 




Leticia Vazquez Cortés, MD Centro De Investigacion Clinica Chapultepec S.A. De C.v. 
General Pena Y Pena 256 Col. Chapultepec Norte  
Morelia, MICHOACÁN, 58260 
Mexico 
Claudia Lorena Urzua Flores, MD 
 
Hospital Cardiologica Aguascalientes 
República De Ecuador No. 200, Las Americas  
Aguascalientes, AGS, 20230 
Mexico 
Netherlands 
Reinoud J B. Blaisse, MD 
 
Rijnstate Ziekhenius 
Wagnerlaan 55  
Arnhem, 6815 AD, 
The Netherlands 
Michiel S. Van der Heijden, MD 
 
Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek 
Plesmanlaan 121 
Amsterdam, 1066 CX,  
The Netherlands 
Ronald de Wit, MD 
 
Erasmus Medisch Centrum 
Daniel den Hoed Cancer Center 
Groene Hilledijk 301 
Oncologisch Centrum 
Rotterdam,3075 EA,  
The Netherlands 
Fransiscus L.G. Erdkamp, MD 
 
Zuyderland MC 
Dr. H. Van Der Hoffplein 1 
Sittard – Geleen, 6162 BG, 
The Netherlands 




Universitair Medisch Centrum Maastricht 
P. Debyelaan 25  
Maastricht, 6229 HX,  
The Netherlands 
Poland 
Joanna Wojcik-tomaszewska, MD Copernicus Podmiot Leczniczy Sp.Z O.o. 
Al. Zwycięstwa 31/32 Dzial Badan Klinicznych 
Gdansk, 80-219 
Poland 
Piotr Tomczak, MD 
 
Szp.kliniczny Przemienienia Panskiego Um 
Im.k.marcinkowskieg 
Ul. Szamarzewskiego 82/84 
Klinika Onkologii; Oddzial Chemioterapii 
Poznan, 60-569 
Poland 
Bozena Sikora-Kupis, MD 
 
Magodent Sp. Z O.o. 
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Michael Schenker, MD 
 
Centrul De Oncologie Sf. Nectarie SRL 
Str. Caracal nr. 23a, Parter Si Demisol, Bloc 17a  
Craiova, DOLJ, 200347 
Romania 
Alina Amalia Herzal, MD 
 
Spitalul Judetean De Urgenta "dr. Constantin Opris" 
Str. George Cosbuc, Nr. 31 
Baia Mare, 430031 
Romania 
Anghel Adrian Udrea, MD 
 
S.C. Medisprof SRL 
Piata 1 Mai Nr. 3 
Cluj-Napoca, Cluj, 400058 
Romania 
Russian Federation 
Petr Karlov, MD 
 
St. Petersburg City Clinical Oncological Dispensary 
56 Veteranov Prospect  
Saint-Petersburg, 198255 
Russian Federation 
Sufia Z. Safina, MD 
 
Republic Oncology Dispensary Of MoH of Republic 
Tatarstan 
29, Sibirskiy Trakt 




Moscow Scientific and Research Oncology Institute 
3, 2-oy Botkinskiy Proezd 
Moscow, 125284 
Russian Federation 
Andrey Semenov, MD 
 
GIoPHS Ivanovo Regional Clinical Oncology Dispensary 
5 Lubimova Street 
Ivanovo, 153040  
Russian Federation 
Roman Fomkin, MD 
 
Saratov State Medical University 




Enrique Grande Pulido, MD 
 
Hospital Universitario Ramon y Cajal 
Ctra. Colmenar Viejo, Km 9.1 
Oficina De Ensayos Clínicos/serv.onco  Planta - 2 Dcha 
Madrid, MADRID, 28034 
Spain 
F. Xavier García Del Muro, MD 
 
Hospital Duran I Reynals 
Avda.castelldefels, Km 2.7 
Oncología  
Barcelona, BARCELONA, 08907 
Spain  
Juan Ignacio Delgado Mignorance 
 
Hospital Infanta Cristina 
Avda. De Elvas, S/n  
Badajoz, BADAJOZ, 06080 
Spain 
Daniel Castellano Gauna, MD 
 
Hospital Universitario 12 De Octubre 
Avenida de Cordoba 
Servicio De Oncología  Edificio De Maternidad, 2ª Planta 
Madrid, MADRID, 28041 
Spain 
Alejo Rodríguez-Vida, MD 
 
Hospital del Mar 
Passeig Maritim, 25-29  
Barcelona, BARCELONA, 08003 
Spain 
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Taiwan 
Yu-Li Su, MD 
 
Chang Gung Memorial Hospital - Kaohsiung 
No.123, Dapi Rd., Niaosong Shiang 
7f. Blood Smear Exam Rm. 
Kaohsiung, 83301 
Taiwan 
Yen-Chuan Ou, MD 
 
Taichung  Veterans General  Hospital 
No 160 Taichung Kuan Road, Section 3 
Prostate Disease Center  1f OPD 
Taichung, 40705 
Taiwan 
Chien-Liang Lin, MD 
 
Chi-Mei Medical Center, Liouying 
No. 201, Taikang Village,                     B2 5 Building  
Tainan, 73657 
Taiwan 
Wen-Pin Su, MD 
 
National Cheng Kung University Hospital 
138, Sheng Li Road 
Clinical Research Center  6f OPD Building 
Tainan, 70403 
Taiwan 
Chia-Chi Lin, MD 
 
National Taiwan University Hospital 
No 1 Changde St. 
Rm.6451,4f, 6 West Building 
Taipei, 10048 
Taiwan 
Su-Peng Yeh, MD 
 
China Medical University Hospital 
No 2, Yuh-Der Rd.,  
Taichung (R.O.C), 40447 
Taiwan 
Turkey 
Irfan Çiçin, MD 
 




Hakan Harputluoglu, MD 
 
Inonu University Medical Faculty 
Inonu University,turgut Ozal Medical Center, 
Elazig Yolu 15.km  
Malatya, TURKEY, 44280 
Turkey 
Mustafa Erman, MD 
 
Hacettepe University Faculty Of Medicine 
Tip Fakultesi Hastanesi Sihhiye 
Ankara, 06100 
Turkey 
Hasan Senol Coskun, MD 
 
Akdeniz University Medical Faculty  
Dumlupinar Bulvari Kampus 
Antalya, 07059 
Turkey 







Yurii Golovko, MD 
 
Kyiv Regional Clinical Oncology Dispensary 
1, Baggovutivska Street 
Kyiv, 04107 
Ukraine 
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Igor Bondarenko, MD 
 
Dnipropetr City Multif Cli Hosp 4 Dnip Regi Council, Dep Che 
31 Blyzhnya Str 
Dnipropetrovsk, 49102, Ukraine 
Ivan Sinielnikov, MD 
 
Volyn Regional Oncological Center 




Thomas Powles, MD 
 
St Bartholomew’s Hospital 
Barts Health NHS trust 
West Smithfield, London, EC1A 7BE 
United Kingdom 
Simon Crabb, MD 
 
University Hospital Southampton NHS FOUNDATION 
TRUST,  
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Table S1: Baseline demographics, first 437 randomised patients 
  
Ramucirumab +  
docetaxel 
(n=216) 
Placebo +  
docetaxel 
(n=221) 
Median age, years (range) 65 (34-86) 66 (34-83) 
    ≥ 65 years 113 (53) 119 (54) 
Male sex 175 (81) 176 (80) 
Race   
White 159 (74) 160 (72) 
Asian 54 (25) 60 (27) 
ECOG performance status   
0 99 (46) 102 (46) 
1 113 (52) 119 (54) 
Geographical region   
    North America 17 (8) 19 (9) 
    Europe/Other 146 (68) 145 (66) 
    East Asia 53 (25) 57 (26) 
Histology   
    Pure transitional cell 169 (78) 174 (79) 
    Mixed histology 40 (19) 42 (19) 
    Missing  7 (3) 5 (2) 
Primary site of tumour   
    Bladder 136 (63) 138 (62) 
    Renal pelvis 30 (14) 35 (16) 
    Ureter 32 (15) 29 (13) 
    Urethra 5 (2) 5 (2) 
    Other 10 (5) 14 (6) 
    Missing 3 (1) 0 
Visceral disease 145 (67) 153 (69) 
    Lung metastases 78 (36) 102 (46) 
    Liver metastases 64 (30) 55 (25) 
    Bone metastases 47 (22) 46 (21) 
    Adrenal gland 13 (6) 8 (4) 
    Kidney 7 (3) 7 (3) 
    Spleen 3 (1) 3 (1) 
    Other 30 (14) 20 (9) 
Lymph node only metastases 46 (21) 39 (18) 
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Creatinine clearance   
   <60 mL/min 92 (43) 101 (46) 
   ≥60 mL/min 119 (55) 118 (53) 
   Missing 5 (2) 2 (<1) 
Haemoglobin concentration <10 g/dL 30 (14) 30 (14) 
Completion or disc of most recent therapy < 3 months 96 (44) 102 (46) 
Number of Bellmunt risk factors†   
    0 3 (1) 0 
    1 82 (38) 85 (38) 
    2 74 (34) 92 (42) 
    3 56 (26) 37 (17) 
    4 1 (<1) 7 (3) 
Prior adjuvant therapy   
    Adjuvant 32 (15) 50 (23) 
    Neo-adjuvant 28 (13) 34 (15) 
    No prior adjuvant 144 (67) 123 (56) 
Prior therapies†   
   Cisplatin-based 134 (62) 149 (67) 
   Carboplatin-based 75 (35) 66 (30) 
   Immune checkpoint inhibitor 14 (6) 19 (9) 
Abbreviation: disc = discontinuation; ECOG = Eastern Cooperative Oncology Group. 
Data are n (%) unless otherwise indicated. 
†Bellmunt risk factors24,25 included visceral metastases, haemoglobin <10 g/dL, ECOG performance 
status score >0, and time since completion or discontinuation of previous therapy of <3 months. 
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Platinum-based therapy 257 (98) 261 (98) 
   Cisplatin 159 (60) 182 (68) 
   Carboplatin 95 (36) 78 (29) 
   Oxaliplatin 1 (<1) 0 
   Platinum, not otherwise specified 2 (<1) 1 (<1) 
Non-platinum-based therapy 257 (98) 261 (98) 
   Gemcitabine 231 (88) 236 (88) 
   Methotrexate/Vinblastine/Doxorubicin 16 (6) 16 (6) 
   Other 2 (<1) 5 (2) 
      Epirubicin/Methotrexate/Mitomycin 1 (<1) 0 
      Epirubicin/Methotrexate 0 1 (<1) 
      Methotrexate/Vinblastine 1 (<1) 1 (<1) 
      Etoposide 0 1 (<1) 
      Methotrexate sodium/Vinblastine 0 1 (<1) 
      Paclitaxel 1 (<1) 1 (<1) 
   None 7 (3) 4 (1) 
Immune checkpoint inhibitor therapy 19 (7) 26 (10) 
   Atezolizumab 10 (4) 10 (4) 
   Pembrolizumab 5 (2) 9 (3) 
   Durvalumab 1 (<1) 2 (<1) 
   Nivolumab 0 2 (<1) 
   Pembrolizumab or placebo 0 1 (<1) 
   Nivolumab or placebo 1 (<1) 0 
   Anti-PD-L1, not otherwise specified 1 (<1) 1 (<1) 
   Bgba317 (anti-PD-1) 1 (<1) 1 (<1) 
Antiangiogenic therapy 0 1 (<1) 
   Ramucirumab 0 1 (<1) 
All Other 1 (<1) 3 (1) 
   Emactuzumab 1 (<1) 0 
   Denosumab 0 1 (<1) 
   Ayurvedic Preparation, not otherwise specified 0 1 (<1) 
   Cancer peptide vaccine 0 1 (<1) 
Abbreviation: ITT = intent-to-treat. 
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Placebo +  
docetaxel 
(n=265) 
Ramucirumab or placebo 
  
   Number of patients 258 265 
   Median duration of therapy (IQR), weeks 12·1 (6-21) 9·9 (6-21) 
   Median number of cycles (IQR) 4 (2-7) 3 (2-6) 
   No. of patients completing at least 2 cycles, (%) 226 (88) 236 (89) 
   No. of patients completing at least 4 cycles, (%) 136 (53) 127 (48) 
   No. of patients completing at least 6 cycles, (%) 95 (37) 87 (33) 
   No. of patients completing at least 8 cycles, (%) 56 (22) 51 (19) 
   Median relative dose intensity (IQR) 99·6 (94.5-100.1) 99·6 (95·5-100·1) 
Docetaxel 
  
   Number of patients 258 265 
   Median duration of therapy (IQR), weeks 12·1 (6-18) 9·9 (6-18) 
   Median number of cycles (IQR) 4 (2-6) 3 (2-6) 
   No. of patients completing at least 2 cycles, (%) 228 (88) 233 (88) 
   No. of patients completing at least 4 cycles, (%) 137 (53) 128 (48) 
   No. of patients completing at least 6 cycles, (%) 93 (36) 84 (32) 
   No. of patients completing at least 8 cycles, (%) 19 (7) 17 (6) 
   Median relative dose intensity (IQR) 98·3 (90·9-100·1) 98·8 (92·9-100·1) 











Ramu-00084475 Draft for Lancet 26-July-2017 
Table S4: Investigator-assessed efficacy endpoints, first 437 randomised patients 










  Deaths or disease progressions, no. (%) 158 (73) 183 (83) 
 
  Median, months (95% CI) 4·07 (2·96 to 4·47) 2·76 (2·60 to 2·96) 
 
  Hazard ratio (95% CI) 0·.757 (0·607 to 0·943) 0·0118 
  3-month PFS rate, % (95% CI) 57·1 (49·9 to 63·7) 42·3 (35·5 to 49·0) 0·0028 
  6-month PFS rate, % (95% CI) 28·5 (22·0 to 35·3) 18·9 (13·7 to 24·7) 0·0309 
  9-month PFS rate, % (95% CI) 16·5 (11·0 to 22·9) 10·0 (6·1 to 14·9) 0·0862 
  12-month PFS rate, % (95% CI) 11·9 (7·1 to 18·0) 4·5 (1·5 to 10·1) 0·0374 
Best overall response, No. (%) 
   
  Complete response  9 (4·2) 3 (1·4)  
  Partial response  44 (20·4) 28 (12·7)  
  Stable disease  84 (38·9) 93 (42·1)  
  Progressive disease  49 (22·7) 73 (33·0)  
  Not evaluable 30 (13·9) 24 (10·9)  
Objective response rate, % (95%CI) 24·5 (18·8 to 30·3) 14·0 (9·4 to 18·6) N/A 
Disease control rate, % (95%CI) 63·4 (57·0 to 69·8) 56·1 (49·6 to 62·7) N/A 
Abbreviations: CI = confidence interval; N/A = not applicable due to gatekeeping trial design; no. = 
number; PFS = progression-free survival 
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Any 15 (6) 11 (4) 
Sepsis 4 (2) 0 
Death† 1 (<1) 2 (<1) 
Renal failure 2 (<1) 0 
Pneumonia 0 2 (<1) 
Pneumonitis 1 (<1) 1 (<1) 
Basilar artery thrombosis 1 (<1) 0 
Cardiac arrest 1 (<1) 0 
Enterovesical fistula 1 (<1) 0 
Gastric haemorrhage 1 (<1) 0 
Neutropenic sepsis 1 (<1) 0 
Pneumonia aspiration 1 (<1) 0 
Respiratory tract infection 1 (<1) 0 
Asthenia 0 1 (<1) 
Lung infection 0 1 (<1) 
Pulmonary embolism 0 1 (<1) 
Pulmonary hypertension 0 1 (<1) 
Sudden death 0 1 (<1) 
Toxic shock syndrome 0 1 (<1) 
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